TICKERNERD
Menu
XBIOXBIOHealthcare · Biotechnology

XBIO Stock Forecast: Xenetic Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.58
+7.19% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$8.4M
Ticker Nerd rank
39 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
+9.1%
1M
+32.6%
YTD
+65.0%
1Y
+27.0%
From 52W high
−65.4%
From 52W low
+77.2%
$2
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xenetic Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Volatility
75
Growth
65
Value
55
Momentum
42
Quality
39
Issuance
33
Accruals
27
Revisions
25

Size (93): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$3$4$5$6$7Oct 25Jan 26Apr 26Jul 26XBIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
5 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
22 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
20 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
16 May 2023HC Wainwright & Co.DowngradeNeutral—
11 Apr 2023HC Wainwright & Co.ReiteratesBuy$4.00
2 May 2022HC Wainwright & Co.MaintainsBuy$5.00 → $4.00
11 Jan 2021HC Wainwright & Co.MaintainsBuy$2.00 → $5.00
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
20 Dec 2016Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

XBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Xenetic Biosciences, Inc. (XBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
2.6×

Cheaper than 47% of US stocks

Price / book
1.1×

Cheaper than 69% of US stocks

EV / EBITDA
−0.7×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
12.0%

Higher than 57% of US stocks

Earnings growth (YoY)
12.0%

Higher than 51% of US stocks

Gross margin
—
Operating margin
−147.1%

Higher than 12% of US stocks

Net margin
−75.9%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−47.0%

Higher than 22% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

XBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XBIOXenetic Biosciences, Inc.$8.4M
39
AZTRAzitra, Inc.$8.0M
28
TRAWTraws Pharma, Inc.$8.0M
48
ERNAErnexa Therapeutics, Inc.$7.9M
34
APREAprea Therapeutics, Inc.$7.9M
44
AIMAIM ImmunoTech, Inc.$7.9M
20
CNSPCNS Pharmaceuticals, Inc.$8.5M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenetic Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XBIO news & analysis

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Accesswire · 7 Aug 2026positive

Xenetic Biosciences reported its second quarter 2026 financial results and provided a corporate update on the advancement of its proprietary DNase platform, highlighting positive preclinical data presented at the ASCO Annual Meeting and expanded collaborative research initiatives.

Why it matters — XBIO watchers would care because the company is generating translational data and pursuing non-dilutive funding through royalties to support its core DNase platform development, which could strengthen the scientific case for future clinical trials.

FAQ

Frequently asked questions about XBIO stock

Is XBIO stock a buy right now?

Of the 1 analysts covering Xenetic Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenetic Biosciences, Inc. 39 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XBIO?

As at 22 Aug 2026, Xenetic Biosciences, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the XBIO stock forecast for 2030?

No analyst covering Xenetic Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIO are extrapolating price history, which says nothing about the business.

How has XBIO stock performed over the past year?

Xenetic Biosciences, Inc. returned +27.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenetic Biosciences, Inc. do?

Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing novel therapies for life-threatening diseases.

What is the latest news on XBIO?

The most recent item we track (Accesswire, 7 Aug 2026): "Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform". Xenetic Biosciences reported its second quarter 2026 financial results and provided a corporate update on the advancement of its proprietary DNase platform, highlighting positive preclinical data presented at the ASCO Annual Meeting and expanded collaborative research initiatives.

Company

About Xenetic Biosciences, Inc.

Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing novel therapies for life-threatening diseases. Its primary function is the advancement of next-generation biologics by leveraging its innovative and proprietary drug delivery platform technology called PolyXen™. This platform is designed to extend the efficacy and improve the pharmacokinetics of biologic drugs. With a strong emphasis on oncology, Xenetic Biosciences is at the forefront of creating novel therapeutics with the potential to significantly impact the healthcare industry. The company is involved in research and development, aiming to produce targeted therapies that can enhance the standard of care in unmet medical needs. It engages with strategic collaborations and partnerships to spearhead its development programs, maximizing the potential for clinical success. Xenetic Biosciences plays a vital role in the biopharmaceutical sector by contributing to scientific advancements and addressing critical medical challenges. Headquartered in Framingham, Massachusetts, this company represents a key player in the ongoing pursuit of effective and innovative medical treatments.

CEO Mr. James F. Parslow · 2 employees · United States · https://www.xeneticbio.com